
Conference Coverage
21 days ago
Elevate-Derm Summer Clinical Pearlsabout 1 month ago
Securing GLP-1 Access and Exploring Hidradenitis Suppurativa Trialsabout 1 month ago
GLP-1 Candidacy and Prescribing Considerations in PsoriasisLatest News

Experts Explore Individualized Treatment Strategies for Psoriasis

Q&A: What Phase 2 Nemolizumab Data Mean for Young Children With Eczema

Topical Docetaxel Enters Development for Extramammary Paget’s Disease

Q&A: Strategies for Protecting Skin in Winter, With Jeanine B. Downie, MD

Weighing Cross-Trial Data and Patient Timelines in Alopecia Areata Treatment
Videos

Shorts










Dermatology Times Digital Edition









All News

For Healthy Skin Month, a dermatology nurse practitioner shares why sunscreen matters in winter and how clinicians can close gaps in skin cancer screening.

Learn why indoor tanning remains a preventable source of melanoma, what research suggests about why some patients experience difficulty stopping, and how a clinical pilot called TanPrevent could connect education with follow-up support to help them quit and stay quit.

Bioelements and Celluma partnered to educate estheticians on integrating LED light therapy into customized facial treatments for acne and aging skin.

FDA implements updated iPLEDGE REMS requirements for isotretinoin, allowing at-home pregnancy testing and reducing prescription and counseling burdens.

Bosakitug failed to meet primary and secondary endpoints in a phase 2 atopic dermatitis trial despite evidence of TSLP target engagement.

Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.

Hypochlorous acid sprays are trending as a post-gym skin care essential, but can they actually prevent sweat-related breakouts?

Clinicians discuss how type 2 inflammation informs treatment decisions across AD, prurigo nodularis, CSU, and bullous pemphigoid.

A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.

At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.

Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.

October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.

Gaurav Singh, MD, MPH, FACMS, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.

A 2026 study links Agent Orange exposure to higher odds of acral melanoma in US veterans, highlighting the importance of early detection.

Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.























